Physician profile
Mark Larson
NPI 1831651868
$2,003.49
in general payments reported to CMS, 2019-2025
10 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,298 · 2024: $288 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041 · Travel and Lodging: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.02 |
| Travel and Lodging | $962.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,341.84 | 2023-2025 | Clareon, Hydrus Microstent |
| Amgen INC. | $139.33 | 2024 | Tepezza |
| Rxsight INC | $131.60 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $114.65 | 2024-2025 | |
| Glaukos Corporation | $112.76 | 2024-2025 | Idosetr, Istent Infinite, Photrexa |
| Ocular Therapeutix, INC. | $57.84 | 2025 | Dextenza |
| Bausch & Lomb Americas INC. | $42.16 | 2025 | Vyzulta, Envista Envy Iol |
| Dompe US, INC. | $35.36 | 2025 | Oxervate |
| Thea Pharma INC. | $15.05 | 2024 | Iyuzeh |
| New World Medical,INC. | $12.90 | 2025 | Streamline, Kahook Dual Blade, Via360 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.